Frontiers | Safety and Efficacy of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis | Medicine
The Roxadustat Chronicles: A Two-Article NephJC — NephJC
Phase 3 clinical trials of Roxadustat. | Download Scientific Diagram
Roxadustat Treatment for Anemia in Dialysis | NEJM Resident 360 <meta property="twitter:image" content="https://resident360files.nejm.org/image/upload/c_fit,f_auto,h_120,w_120/v1538599218/u8buf4o8mgdxgmfcczjk.png" /> <meta property="og:image" content ...
Randomized Study on the Efficacy of Standard Versus Low Roxadustat Dose for Anemia in Patients on Peritoneal Dialysis - ScienceDirect
Phase 3 Study of Roxadustat to Treat Anemia in Non–Dialysis-Dependant CKD - ScienceDirect
Clinical trial paper that made anemia drug look safer than it is will be retracted – Retraction Watch
Two Phase 3 Studies on Ophthalmologic Effects of Roxadustat Versus Darbepoetin - Kidney International Reports
Roxadustat in clinical trials with CRP. | Download Scientific Diagram
Roxadustat in phase III clinical trials. | Download Scientific Diagram
Phase 3 Study of Roxadustat to Treat Anemia in Non–Dialysis-Dependant CKD - ScienceDirect
The Roxadustat Chronicles: A Two-Article NephJC — NephJC
The Next Big Biotech Blow-Up (NASDAQ:FGEN) | Seeking Alpha
Edgar V. Lerma 🇵🇭 on Twitter: "Roxadustat - 30% lower risk of MACE and 34% lower risk of MACE+ than epoetin alfa & with a trend towards lower all-cause mortality relative to
FDA slaps AstraZeneca, Fibrogen with last-minute roxadustat AdComm, cuing another delay for anemia drug | Fierce Pharma
Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non–Dialysis-Dependent CKD | American Society of Nephrology
Completed Phase 2 and 3 Studies of Roxadustat (FG-4592), Vadadustat... | Download Table
FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease | FibroGen, Inc.
Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis | NEJM
Phase 3 Study of Roxadustat to Treat Anemia in Non–Dialysis-Dependant CKD - ScienceDirect
Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study - American Journal of Kidney
fgen-10k_20151231.htm
Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study | American Society of Nephrology
Roxadustat for the treatment of anemia in patients with chronic kidney diseases: a meta-analysis | Aging
